Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | HTR1B | P28222 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230016 | 0.94 | KCNA3 (0.59) | KCNA3ALDH1A1KDM4EUSP2LMNA | |
| SCHEMBL7976554 | 0.90 | KCNA3 (0.52) | KCNA3ALDH1A1LTA4HHTR1BMEN1 | |
| SCHEMBL10391332 | 0.90 | KCNA3 (0.48) | KCNA3ALDH1A1KDM4EUSP2LMNA | |
| SCHEMBL24041852 | 0.87 | CA1 (0.51) | KCNA3DRD2DRD4DRD3 | |
| SCHEMBL3939161 | 0.85 | PKM (0.47) | KCNA3ALDH1A1KDM4EHTR1BMEN1 | |
| SCHEMBL18614957 | 0.84 | SMN1; SMN2 (0.57) | ALDH1A1KDM4ELMNAMEN1HTT | |
| SCHEMBL9714281 | 0.84 | LTA4H (0.58) | KCNA3LTA4HMEN1HTTKMT2A | |
| SCHEMBL17501637 | 0.83 | MAPT (0.50) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL4631786 | 0.82 | LMNA (0.54) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL22749055 | 0.81 | KDM4E (0.48) | ALDH1A1KDM4EUSP2LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104302623-A | Piperidine compound and pest-control use therefore | SUMITOMO CHEMICAL CO | 2015-01-21 | — | — | CN | disclosed |
| WO-2008096093-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096093-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | disclosed |
| CN-100384836-C | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2008-04-30 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| CN-1426405-A | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-06-25 | — | — | CN | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-4937268-A | TREATMENT OF ASTHMA, CHRONIC BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1990-06-26 | — | — | US | disclosed |
| EP-0286242-A2 | Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | KCNA3 1986/4885ALDH1A1 2504/4885KDM4E 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.